Clopidogrel versus Aspirin in Patients with Atherothrombosis
- 78 Downloads
Background: Atherothrombosis represents a leading cause of morbidity and mortality worldwide. Given the prominent role of platelet aggregation in atherothrombosis, antiplatelet therapy forms the cornerstone of treatment, with proven efficacy in the secondary prevention of atherothrombotic events. Although clopidogrel seems to be superior to aspirin in terms of risk reduction for an atherothrombotic event, whether this clinical advantage is cost effective in Greece is unknown.
Objective: The aim of this study was to conduct a cost-effectiveness analysis comparing clopidogrel with aspirin in the secondary prevention of atherothrombotic events in patients with peripheral artery disease, a recent stroke or a recent myocardial infarction, from the third-party-payer perspective in Greece.
Methods: A Markov model with a 6-month cycle length was developed. Transition probabilities used in the model were obtained from the event rates reported in the CAPRIE trial. The effect of clopidogrel was applied only during the first 2 years of the model. Utility data were used to estimate quality-adjusted life-years (QALYs). Costs (for the year 2012) assigned to each health state included antiplatelet treatment cost, cost for the management of adverse events related to antiplatelet therapy and the direct healthcare cost of patients (i.e. concomitant medication, hospitalization, outpatient visits, rehabilitation, laboratory and imaging diagnostic examinations as well as interventions) in the acute and follow-up phase, separately. The incremental cost-effectiveness ratio (ICER) was calculated for life-years (LYs) and QALYs, separately. A probabilistic sensitivity analysis was conducted in order to evaluate the impact of the variation that characterizes the majority of model parameters to the cost-effectiveness results.
Results: The Markov analysis revealed that the discounted survival was 11.83 (95% CI 11.40, 12.22) years and 12.17 (95% CI 11.75, 12.55) years in the aspirin and clopidogrel treatment groups, respectively, a difference of 0.34 (95% CI 0.09, 0.618) LYs. The corresponding discounted QALYs were 8.63 (95% CI 8.34, 8.90) and 8.84 (95% CI 8.54, 9.10), respectively, a difference of 0.21 (95% CI 0.05, 0.37) QALYs. The cumulated lifetime costs per patient were €20 678 (95% CI 19 675, 21 724) and €21 688 (95% CI 20 649, 22 773), for aspirin and clopidogrel treatment arm, respectively. The ICER for clopidogrel was calculated to be €4038 (95% CI 2743, 7837) for each LY saved and €5518 (95% CI 3358, 12921) for each QALY saved.
Conclusion: The analysis indicates that clopidogrel is cost effective for the secondary prevention of atherothrombotic events in the Greek setting. These findings are in line with those reported in other European countries.
KeywordsAspirin Ischaemic Stroke Clopidogrel Secondary Prevention Peripheral Arterial Disease
This study was funded by Sanofi-Aventis Hellas. NM received an unrestricted grant from Sanofi-Aventis Hellas. However, the study sponsor had no interference in the study design, data collection or writing of the manuscript. None of the rest of the authors has any personal or financial conflict of interest.
GK adapted the model, conducted the analyses, interpreted the results and wrote the manuscript. VF contributed to the paper writing and results interpretation. NM supervised the study, contributed to results interpretation, reviewed the manuscript and he is the guarantor for the overall content.
- 3.World Health Organization. Cardiovascular diseases (CVD). Fact sheet no. 317 [online]. Available from URL: www.who.int/mediacentre/factsheets/fs317/en/print.html [Accessed 2010 Oct 8]
- 7.Sanofi Aventis. Plavix® (clopidogrel bisulfate tablets): US prescribing information [online]. Available from URL: http://products.sanofi-aventis.us/plavix/plavix.html [Accessed 2010 Oct 8]
- 14.Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102: 624–9PubMedCrossRefGoogle Scholar
- 16.Waksman R, Ajani AE, White RL, et al. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma-radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS). Circulation 2001; 103: 2332–5PubMedCrossRefGoogle Scholar
- 24.Mahoney EM, Mehta S, Yuan Y, et al. Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. Am Heart J 2006; 151: 219–27PubMedCrossRefGoogle Scholar
- 29.Greek Ministry of Health. Drug price bulletin [online]. Available from URL: http://www.yyka.gov.gr/ [Accessed 2012 Jan 11]
- 31.Maniadakis N, Fragoulakis V, Pallis AG, et al. Economic evaluation of docetaxel-gemcitabine versus vinorelbine-cisplatin combination as front-line treatment of patients with advanced/metastatic non-small-cell lung cancer in Greece: a cost-minimization analysis. Ann Oncol 2010; 21: 1462–7PubMedCrossRefGoogle Scholar
- 33.Government Gazette. Presidential Decree 127/2005. Increase of salaries of doctors’ visits. 2005; Athens, GreeceGoogle Scholar
- 34.Government Gazette. Common Ministerial Decree Y4a/OIK.1320/1998. Definition of hospital charges. 1998; Athens, GreeceGoogle Scholar
- 35.Government Gazette. Presidential Decree 427/1991, FEK 156. Costing of medical practices. 1991; Athens, GreeceGoogle Scholar
- 36.Government Gazette. Presidential Decree 157/1991, FEK 62. Increase of salaries of doctors’ visits and medical and dental practices. 1991; Athens, GreeceGoogle Scholar
- 37.Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation. Handbooks in health economic evaluation. New York: Oxford University Press Inc, 2006Google Scholar
- 42.Waksman R, Ajani AE, Pinnow E, et al. Twelve versus six months of clopidogrel to reduce major cardiac events in patients undergoing gamma-radiation therapy for in-stent restenosis: Washington Radiation for In-Stent restenosis Trial (WRIST) 12 versus WRIST PLUS. Circulation 2002; 106: 776–8PubMedCrossRefGoogle Scholar
- 44.Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of peri-procedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111: 2099–106PubMedCrossRefGoogle Scholar